Access the full text.
Sign up today, get DeepDyve free for 14 days.
W. Frishman, C. Ram, F. Mcmahon, S. Chrysant, A. Graff, J. Kupiec, H. Hsu (1995)
Comparison of Amlodipine and Benazepril Monotherapy to Amlodipine Plus Benazepril In Patients with Systemic Hypertension: A Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group StudyThe Journal of Clinical Pharmacology, 35
A. Chobanian, G. Bakris, H. Black, W. Cushman, L. Green, J. Izzo, Daniel Jones, B. Materson, S. Oparil, J. Wright, E. Roccella (2003)
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.Hypertension, 42 6
L. Cubeddu, J. Aranda, B. Singh, M. Klein, J. Brachfeld, E. Freis, J. Román, T. Eades (1986)
A comparison of verapamil and propranolol for the initial treatment of hypertension. Racial differences in response.JAMA, 256 16
K. Jamerson, Annette Champion, Qian Zhou, C. Pepine (2005)
P-286: Verapamil- and atenolol-based strategies are equally effective in black patients with hypertension and coronary artery disease: A subanalysis of the international verapamil SR-trandolapril study (INVEST)American Journal of Hypertension, 18
K. Jamerson, G. Bakris, C. Wun, B. Dahlöf, M. Lefkowitz, S. Manfreda, B. Pitt, E. Velazquez, M. Weber (2004)
Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension.American journal of hypertension, 17 9
P. Granier, M. Douste-Blazy, P. Trédez, D. Conte, E. Galinier (1990)
Improvement in left ventricular hypertrophy and left ventricular diastolic function following verapamil therapy in mild to moderate hypertensionEuropean Journal of Clinical Pharmacology, 39
Peter Stone (1987)
Calcium antagonists for Prinzmetal's variant angina, unstable angina and silent myocardial ischemia: therapeutic tool and probe for identification of pathophysiologic mechanisms.The American journal of cardiology, 59 3
L. Hansson, T. Hedner, P. Lund-johansen, S. Kjeldsen, L. Lindholm, J. Syvertsen, J. Lanke, U. Faire, B. Dahlöf, B. Karlberg (2000)
Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) studyThe Lancet, 356
SR Calan (2003)
(verapamil hydrochloride) sustained-release oral caplets prescribing information
N. Morel, Vitali Buryi, O. Féron, J. Gomez, M. Christen, T. Godfraind (1998)
The action of calcium channel blockers on recombinant L‐type calcium channel α1‐subunitsBritish Journal of Pharmacology, 125
H. Krum (1997)
Critical assessment of calcium antagonists.Australian family physician, 26 7
Morris Brown, C. Palmer, A. Castaigne, P. Leeuw, G. Mancia, T. Rosenthal, L. Ruilope (2000)
Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)The Lancet, 356
SR Cardenc (2000)
(nicardipine hydrochloride) prescribing information
H. Kroemer, J. Gautier, P. Beaune, C. Henderson, C. Wolf, M. Eichelbaum (1993)
Identification of P450 enzymes involved in metabolism of verapamil in humansNaunyn-Schmiedeberg's Archives of Pharmacology, 348
S. Voyaki, J. Staessen, L. Thijs, J. Wang, A. Efstratopoulos, W. Birkenhäger, P. Leeuw, G. Leonetti, C. Nachev, J. Rodicio, J. Tuomilehto, R. Fagard (2001)
Follow-up of renal function in treated and untreated older patients with isolated systolic hypertensionJournal of Hypertension, 19
M. Weir, P. Hall, M. Behrens, J. Flack (1997)
Salt and blood pressure responses to calcium antagonism in hypertensive patients.Hypertension, 30 3 Pt 1
William Cushman, Jerome Cohen, Randolph Jones, T. Marbury, Robert Rhoades, Leo Smith (1998)
Comparison of the fixed combination of enalapril/diltiazem ER and their monotherapies in stage 1 to 3 essential hypertension.American journal of hypertension, 11 1 Pt 1
J. Chalmers (2004)
Comparison of various blood pressure lowering treatments on the primary prevention of cardiovascular outcomes in recent randomised clinical trials.Clinical and experimental hypertension, 26 7-8
G. Bakris, D. Sica, V. Ram, T. Fagan, P. Vaitkus, R. Anders (2002)
A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes.American journal of hypertension, 15 1 Pt 1
B. Brenner, M. Cooper, D. Zeeuw, W. Keane, W. Mitch, H. Parving, G. Remuzzi, S. Snapinn, Zhonxin Zhang, S. Shahinfar (2001)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.The New England journal of medicine, 345 12
B. Neal, S. MacMahon, N. Chapman (2000)
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trialsThe Lancet, 356
A. Rubio-Guerra, Carlos Treviño-Gomezharper, L. Rodríguez-López, G. Vargas-Ayala, J. Lozano-Nuevo, Adalberto Arceo-Navarro (2002)
Renoprotective Effects of the Combination Trandolapril/Verapamil in Patients with Type 2 Diabetes Mellitus and HypertensionClinical Drug Investigation, 22
D. Wyse, A. Waldo, J. Dimarco, M. Domanski, Y. Rosenberg, Eleanor Schron, J. Kellen, H. Greene, M. Mickel, J. Dalquist, S. Corley (2002)
A comparison of rate control and rhythm control in patients with atrial fibrillation.The New England journal of medicine, 347 23
SM Voyaki, JA Staessen, L Thijs (2001)
Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial InvestigatorsJ Hypertens, 19
G. Bakris, M. Weir, M. Secic, B. Campbell, Annette Weis-McNulty (2004)
Differential effects of calcium antagonist subclasses on markers of nephropathy progression.Kidney international, 65 6
C. Ersoy, Ş. Imamoğlu, Ferah Budak, E. Tuncel, E. Ertürk, B. Oral (2004)
Effect of amlodipine on insulin resistance & tumor necrosis factor-alpha levels in hypertensive obese type 2 diabetic patients.The Indian journal of medical research, 120 5
J. Widimský (2000)
The fixed combination of verapamil SR/trandolaprilExpert Opinion on Pharmacotherapy, 1
E. Lewis, L. Hunsicker, W. Clarke, T. Berl, M. Pohl, J. Lewis, E. Ritz, R. Atkins, R. Rohde, I. Raz (2001)
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.The New England journal of medicine, 345 12
U. Eriksson, J. Lundahl, C. Bäärnhielm, C. Regårdh (1991)
Stereoselective metabolism of felodipine in liver microsomes from rat, dog, and human.Drug metabolism and disposition: the biological fate of chemicals, 19 5
Matthew Weir, S. Chrysant, David McCarron, M. Canossa-Terris, J. Cohen, Patricia Gunter, Andrew Lewin, Robert Mennella, Lance Kirkegaard, Jennifer Hamilton, Myron Weinberger, A. Weder (1998)
Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives.Hypertension, 31 5
E. Andreadis, G. Tsourous, G. Marakomichelakis, P. Katsanou, M. Fotia, C. Vassilopoulos, E. Diamantopoulos (2005)
High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertensionJournal of Human Hypertension, 19
B. Massie (1998)
Safety of calcium-channel blockers.The Medical letter on drugs and therapeutics, 39 994
R. Viskoper, D. Compagnone, R. Dies, P. Zilles (1997)
Verapamil and trandolapril alone and in fixed combination on 24-hour ambulatory blood pressure profiles of patients with moderate essential hypertensionCurrent Therapeutic Research-clinical and Experimental, 58
M. Cobb, Deborah Johnson, J. Gallo, J. Crawley, P. Cargo, M. Lefkowitz (1995)
Large-Scale Postmarketing Surveillance of Hypertensive Patients Treated with Verapamil.American journal of therapeutics, 2 7
E. Agabiti-Rosei, B. Trimarco, M. Muiesan, J. Reid, A. Salvetti, R. Tang, M. Hennig, H. Baurecht, G. Parati, G. Mancia, A. Zanchetti (2005)
Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA)Journal of Hypertension, 23
D. Sica (2004)
Calcium channel blockers and the kidney.Clinical cornerstone, 6 4
MR Lakshman, DJ Reda, BJ Materson (1999)
Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive AgentsArch Intern Med, 159
J. Wright, G. Bakris, T. Greene, L. Agodoa, L. Appel, J. Charleston, D. Cheek, Janice Douglas-Baltimore, J. Gassman, R. Glassock, L. Hebert, K. Jamerson, J. Lewis, R. Phillips, R. Toto, J. Middleton, S. Rostand (2002)
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.JAMA, 288 19
D. Abernethy, J. Schwartz (1999)
Calcium-antagonist drugs.The New England journal of medicine, 341 19
(2006)
Atlas of end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
H. Black (2004)
Calcium channel blockers in the treatment of hypertension and prevention of cardiovascular disease: results from major clinical trials.Clinical cornerstone, 6 4
(2000)
prescribing information
A. Quiñones-Galvan, A. Pucciarelli, D. Ciociaro, A. Masoni, F. Franzoni, A. Natali, E. Ferrannini (2002)
Metabolic Effects of Combined Antihypertensive Treatment in Patients With Essential HypertensionJournal of Cardiovascular Pharmacology, 40
TH Jafar, CH Schmid, M Landa (2001)
Angiotensin-converting enzyme inhibitors and progression of nondiabctic renal disease. A meta-analysis of patient-level dataAnn Intern Med, 135
G. Bakris, M. Weir, V. Dequattro, F. Mcmahon (1998)
Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy.Kidney international, 54 4
JG Wang, Y Li (2004)
Primary and secondary prevention of stroke by antihyper tensive drug treatmentExpert Rev Neurother, 4
O. Klungel, O. Klungel, S. Heckbert, W. Longstreth, C. Furberg, R. Kaplan, N. Smith, R. Lemaitre, H. Leufkens, A. Boer, B. Psaty (2001)
Antihypertensive drug therapies and the risk of ischemic stroke.Archives of internal medicine, 161 1
S. Anderson, H. Rennke, D. Garcia, B. Brenner, Susan Riley, D. Sandstrom (1989)
Short and long term effects of antihypertensive therapy in the diabetic rat.Kidney international, 36 4
B. Materson, D. Reda, W. Cushman (1995)
Department of veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.American journal of hypertension, 8 2
R. Cooper-DeHoff, R. Kolloch, F. Messerli, E. Handberg, C. Pepine (2004)
1085-197 Blood pressure control, angina episodes, and cardiovascular outcomes in patients with ischemia: The international verapamil/trandolapril studyJournal of the American College of Cardiology, 43
R. Kloner, G. Vetrovec, B. Materson, M. Levenstein (1998)
Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients.The American journal of cardiology, 81 2
D. Magometschnigg, D. Brandt, R. Hofmann, K. Sihorsch, K. Stoschitzky, M. Zangeneh, G. Zenker (1997)
Treatment of left ventricular hypertrophy in hypertensive patients with a combination of verapamil and captopril--a multicenter study.International journal of clinical pharmacology and therapeutics, 35 9
H. Black, W. Elliott, M. Weber, W. Frishman, J. Strom, P. Liebson, C. Hwang, D. Ruff, R. Montoro, V. Dequattro, Danyi Zhang, M. Schleman, M. Klibaner (2001)
One-Year Study of Felodipine or Placebo for Stage 1 Isolated Systolic HypertensionHypertension: Journal of the American Heart Association, 38
JG Fodor, CC Nisoldipine (1997)
efficacy and tolerability in hypertension and ischemic heart diseaseCardiovasc Drugs Ther, 10
J. Gottdiener, D. Reda, David Williams, B. Materson, W. Cushman, Robert Anderson (1997)
Effect of single-drug therapy on reduction of left atrial size in mild to moderate hypertension: comparison of six antihypertensive agents.Circulation, 98 2
B. Falkner (1990)
Differences in Blacks and Whites With Essential Hypertension: Biochemistry and Endocrine State of the Art LectureHypertension, 15
F. Guengerich, W. Brian, M. Iwasaki, M. Sari, Catharina Baeaernhielm, P. Berntsson (1991)
Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4.Journal of medicinal chemistry, 34 6
Matthew Weir (1998)
The rationale for combination versus single-entity therapy in hypertension.American journal of hypertension, 11 10
BM Massie (1998)
The safety of calcium-channel blockersClin Cardiol, 21
E. Saunders, M. Weir, B. Kong, J. Hollifield, James Gray, V. Vertes, J. Sowers, M. Zemel, C. Curry, J. Schoenberger, J. Wright, W. Kirkendall, E. Conradi, P. Jenkins, B. McLean, B. Massie, G. Berenson, W. Flamenbaum (1990)
A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks.Archives of internal medicine, 150 8
R. Toto (2005)
Management of Hypertensive Chronic Kidney Disease: Role of Calcium Channel BlockersThe Journal of Clinical Hypertension, 7
H. Black, W. Elliott, G. Grandits, P. Grambsch, T. Lucente, W. White, J. Neaton, R. Grimm, L. Hansson, Y. Lacourciére, J. Muller, P. Sleight, M. Weber, G. Williams, J. Wittes, A. Zanchetti, R. Anders (2003)
Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.JAMA, 289 16
J. Staessen, Yan Li, L. Thijs, Ji-Guang Wang (2005)
Blood Pressure Reduction and Cardiovascular Prevention: An Update Including the 2003–2004 Secondary Prevention TrialsHypertension Research, 28
T. Thulin, A. Lehtonen, C. Dahlöf, P. Nilsson‐Ehle, L. Engqvist, C. Lagerstedt, E. Berglund (1999)
Long-term effects of diltiazem and atenolol on blood glucose, serum lipids, and serum urate in hypertensive patients. Swedish-Finnish Study Group.International journal of clinical pharmacology and therapeutics, 37 1
M. Lakshman, D. Reda, B. Materson, W. Cushman, E. Freis (1999)
Diuretics and β-Blockers Do Not Have Adverse Effects at 1 Year on Plasma Lipid and Lipoprotein Profiles in Men With HypertensionJAMA Internal Medicine, 159
B. Dahlöf, P. Sever, N. Poulter, H. Wedel, D. Beevers, M. Caulfield, R. Collins, S. Kjeldsen, A. Kristinsson, G. Mcinnes, J. Mehlsen, M. Nieminen, E. O’Brien, J. Östergren (2005)
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled triThe Lancet, 366
Amie Joyce, A. Pedan, P. Girase, M. Rucker, D. Ollendorf (2003)
PCV58 ECONOMIC IMPACT OF SELECTED FIXEDCOMBINATION ANGIOTENSIN-CONVERTING ENZYME INHIBITOR/CALCIUM CHANNEL BLOCKER ANTI-HYPERTENSIVES AMONG PATIENTS WITH DIABETESValue in Health, 6
M. Houston, M. Weir, James Gray, David Ginsberg, Caroline Szeto, Paul Kaihlenen, D. Sugimoto, Mark Runde, M. Lefkowitz (1995)
The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil.Archives of internal medicine, 155 10
P. Stone, R. Gibson, S. Glasser, M. Dewood, J. Parker, D. Kawanishi, M. Crawford, F. Messineo, T. Shook, K. Raby, D. Curtis, R. Hoop, E. Braunwald (1990)
Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina. Differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. The ASIS Study Group.Circulation, 82 6
D. Cummings, P. Amadio, L. Nelson, J. Fitzgerald (1991)
The role of calcium channel blockers in the treatment of essential hypertension.Archives of internal medicine, 151 2
(2005)
(amlodipine besylate) tablets prescribing information
G. Bakris, Mark Williams, L. Dworkin, W. Elliott, Murray Epstein, R. Toto, K. Tuttle, J. Douglas, Willa Hsueh, J. Sowers (2000)
Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.American journal of kidney diseases : the official journal of the National Kidney Foundation, 36 3
C. Held, P. Hjemdahl, N. Rehnqvist, N. Wallén, I. Björkander, Sven Eriksson, L. Forslund, B. Wiman (1997)
Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm.Circulation, 95 10
BE Karlberg, M Andrup, A Oden (2000)
Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Swedish TARKA trialistsBlood Press, 9
J. Neaton, R. Grimm, R. Prineas, J. Stamler, G. Grandits, P. Elmer, J. Cutler, J. Flack, J. Schoenberger, R. Mcdonald (1993)
Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group.JAMA, 270 6
L. Opie (1997)
Pharmacological differences between calcium antagonists.European heart journal, 18 Suppl A
B Neal, S MacMahon, N Chapman (2000)
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ CollaborationLancet, 356
G. Mancia, R. Cooper-DeHoff, Ann Hewkin, S. Kupfer, C. Pepine (2004)
P-229: Association of BP control and frequency of mortality and CV morbidity in hypertensive patients with CAD: the international verapamil SR-trandolapril studyAmerican Journal of Hypertension, 17
W. Frishman, S. Glasser, P. Stone, P. Deedwania, M. Johnson, T. Fakouhi (1999)
Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris.The American journal of cardiology, 83 4
L. Opie (1988)
Calcium channel antagonists part IV: Side effects and contraindications drug interactions and combinationsCardiovascular Drugs and Therapy, 2
Y. Ding, T. Chou, K. Lin (1994)
Effects of long-acting propranolol and verapamil on blood pressure, platelet function, metabolic and rheological properties in hypertension.Journal of human hypertension, 8 4
T. Jafar, C. Schmid, M. Landa, I. Giatras, R. Toto, G. Remuzzi, G. Maschio, B. Brenner, A. Kamper, P. Zucchelli, G. Becker, A. Himmelmann, K. Bannister, P. Landais, S. Shahinfar, P. Jong, D. Zeeuw, J. Lau, A. Levey (2001)
Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal DiseaseAnnals of Internal Medicine, 135
CR DynaCirc (2005)
(isradipine) prescribing information
LA Cardizem (2004)
(diltiazem hydrochloride) prescribing information
G. Bakris, E. Gaxiola, F. Messerli, G. Mancia, S. Erdine, R. Cooper-DeHoff, C. Pepine (2004)
Clinical Outcomes in the Diabetes Cohort of the International Verapamil SR-Trandolapril StudyHypertension, 44
Addison Taylor, O. Shoheiber (2003)
Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy.Congestive heart failure, 9 6
C. Furberg, J. Wright, B. Davis, J. Cutler, M. Alderman, H. Black, W. Cushman, R. Grimm, L. Haywood, F. Leenen, S. Oparil, J. Probstfield, P. Whelton, C. Nwachuku, D. Gordon, M. Proschan, Paula Einhom, C. Ford, L. Piller, I. Dunn, D. Goff, S. Pressel, Judy Bettencourt, Barbara DeLeon, Lara Simpson, J. Blanton, T. Geraci, Sandra Walsh, C. Nelson, Mahboob Rahman, Anne Juratovac, R. Pospíšil, L. Carroll, Sheila Sullivan, J. Russo, G. Barone, Rudy Christian, S. Feldman, T. Lucente, D. Calhoun, Kimo Jenkins, Peggy McDowell, Janice Johnson, C. Kingry, J. Alzate, K. Margolis, Leslie Holland-Klemme, B. Jaeger, J. Williamson, G. Louis, Pamela Ragusa, A. Williard, R. Ferguson, J. Tanner, J. Eckfeldt, R. Crow, J. Pelosi (2002)
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).JAMA, 288 23
H. Knaepler, F. Koch, H. Bugany (1992)
Untersuchungen zur HIV-Inaktivierung in allogenen Knochentransplantaten durch chemische Desinfektion und radioaktive BestrahlungUnfallchirurgie, 18
L. Pichard, G. Gillet, Isabelle Fabre, I. Dalet-Beluche, C. Bonfils, J. Thénot, Patrick Maurel (1990)
Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem.Drug metabolism and disposition: the biological fate of chemicals, 18 5
B. Vogelgesang, H. Echizen, E. Schmidt, M. Eichelbaum (1984)
Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique.British journal of clinical pharmacology, 18 5
D. Abernethy, J. Schwartz (1988)
Pharmacokinetics of Calcium Antagonists Under DevelopmentClinical Pharmacokinetics, 15
JA Staessen, R Fagard, L Thijs (1997)
Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial InvestigatorsLancet, 350
SR Cardizem (2001)
(diltiazem HCL) prescribing information
Timothy Tracy, Kenneth Korzekwa, Frank Gonzalez, I. Wainer (1999)
Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil.British journal of clinical pharmacology, 47 5
W. Frishman (2007)
Calcium Channel Blockers: Differences Between SubclassesAmerican Journal of Cardiovascular Drugs, 7
G. Bakris, K. Griffin, M. Picken, A. Bidani (1997)
Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injuryJournal of Hypertension, 15
S. Hohnloser, K. Kuck, J. Lilienthal (2000)
Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trialThe Lancet, 356
F. Ruschitzka, Thomas Lüscher (1997)
Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease?American heart journal, 134 2 Pt 2
I. Hajjar, T. Kotchen (2003)
Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.JAMA, 290 2
C. Pepine, E. Handberg, R. Cooper-DeHoff, R. Marks, P. Kowey, F. Messerli, G. Mancia, J. Cangiano, D. García-Barreto, M. Keltai, S. Erdine, Heather Bristol, Ms Kolb, G. Bakris, Jerome Cohen, W. Parmley (2003)
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.JAMA, 290 21
M. Nuijten, W. Wittenberg, J. Kosa (2003)
PDB19: THE COST-EFFECTIVENESS OF TARKA FOR PREVENTING RENAL FAILURE IN TYPE 2 DIABETIC PATIENTS WITH HYPERTENSION IN THE US HEALTH CARE SETTINGValue in Health, 6
CC Adalat (2004)
(nifedipine) prescribing information
R. Morris, A. Sebastian, A. Forman, Masae Tanaka, O. Schmidlin (1999)
Normotensive salt sensitivity: effects of race and dietary potassium.Hypertension, 33 1
P. Kearney, Megan Whelton, K. Reynolds, P. Muntner, P. Whelton, Jiang He (2005)
Global burden of hypertension: analysis of worldwide dataThe Lancet, 365
P. Cohn (1994)
Concomitant use of nitrates, calcium channel blockers, and beta blockers for optimal antianginal therapyClinical Cardiology, 17
WH Frishman, CV Ram, FG McMahon (1995)
Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-contiolled, parallel-group study. The Benazepril/Amlodipine Study GroupJ Clin Pharmacol, 35
Amy Smith, R. Toto, G. Bakris (1998)
Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy.Kidney international, 54 3
J. Flack, D. Sica (2005)
Therapeutic Considerations in the African‐American Patient With Hypertension: Considerations With Calcium Channel Blocker TherapyThe Journal of Clinical Hypertension, 7
A. Bilge, D. Atılgan, T. Tükek, M. Özcan, B. Özben, N. Koylan, M. Meriç (2005)
Effects of amlodipine and fosinopril on heart rate variability and left ventricular mass in mild‐to‐moderate essential hypertensionInternational Journal of Clinical Practice, 59
IF Hansen, L Hagerup, B Sigurd (1997)
Treatment with verapamil and trandolapril in patients with congestive heart failure and angina pectoris or myocardial infarction. The DAVIT Study Group. Danish Verapamil Infarction TrialAm Heart J, 134
J. Fodor (2004)
Nisoldipine CC: Efficacy and tolerability in hypertension and ischemic heart diseaseCardiovascular Drugs and Therapy, 10
M. Weber (2002)
Calcium Channel Antagonists in the Treatment of HypertensionAmerican Journal of Cardiovascular Drugs, 2
J. Staessen, L. Thijs, W. Birkenhäger, C. Bulpitt, R. Fagard (1999)
Update on the systolic hypertension in Europe (Syst-Eur) trial. The Syst-Eur Investigators.Hypertension, 33 6
(2002)
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 288
WB Kannel (2001)
Risk stratification: new insights from the Framingham studyAm J Hypertens, 13
K. Landmark, M. Forsman, K. Lindberg, T. Ryman, K. Martmann-Moe, S. Haaverstad, S. Wiel (1995)
Nitrendipine and mefruside in elderly hypertensives: effects on blood pressure, cardiac output, cerebral blood flow and metabolic parameters.Journal of human hypertension, 9 4
T. Hedner (1999)
Progress report on the Nordic diltiazem study (NORDIL): an outcome study in hypertensive patients.Blood pressure, 8 5-6
V. Papademetriou (2004)
From Hypertension to Heart FailureThe Journal of Clinical Hypertension, 6
P. Meredith, H. Elliott (2004)
Dihydropyridine calcium channel blockers: basic pharmacological similarities but fundamental therapeutic differences.Journal of hypertension, 22 9
P. Verdecchia, G. Reboldi, F. Angeli, R. Gattobigio, M. Bentivoglio, L. Thijs, J. Staessen, C. Porcellati (2005)
Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke PreventionHypertension, 46
G Mancia, RM Cooper-Dehoff, AC Hewkin (2004)
Association of BP control and frequency of mortality and CV morbidity in hypertensive patients with CAD: the International Verapamil SR-Trandolapril StudyAm Heart J, 17
J. Staessen, R. Fagard, L. Thijs, H. Celis, G. Arabidze, W. Birkenhäger, C. Bulpitt, P. Leeuw, C. Dollery, A. Fletcher, F. Forette, G. Leonetti, C. Nachev, E. Brien, J. Rosenfeld, J. Rodicio, J. Tuomilehto, A. Zanchetti (1997)
Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertensionThe Lancet, 350
B. Karlberg (2000)
Efficacy and Safety of a New Long-acting Drug Combination, Trandolapril/Verapamil as Compared to Monotherapy in Primary HypertensionBlood Pressure, 9
E. Antman, J. Muller, S. Goldberg, R. Macalpin, M. Rubenfire, B. Tabatznik, C. Liang, F. Heupler, S. Achuff, Nathaniel Reicher, E. Geltman, N. Kerin, R. Neff, E. Braunwald (1980)
Nifedipine therapy for coronary-artery spasm. Experience in 127 patients.The New England journal of medicine, 302 23
T. Takami, Minori Shigematsu (2003)
Effects of Calcium Channel Antagonists on Left Ventricular Hypertrophy and Diastolic Function in Patients with Essential HypertensionClinical and Experimental Hypertension, 25
A. Rubio-Guerra, Adalberto Arceo-Navarro, G. Vargas-Ayala, L. Rodríguez-López, J. Lozano-Nuevo, Carlos Gomez-Harper (2004)
The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes.Diabetes care, 27 7
J. Cabezas-Cerrato, D. García-Estévez, D. Araujo, M. Iglesias (1997)
Insulin sensitivity, glucose effectiveness, and beta-cell function in obese males with essential hypertension: investigation of the effects of treatment with a calcium channel blocker (diltiazem) or an angiotensin-converting enzyme inhibitor (quinapril).Metabolism: clinical and experimental, 46 2
Plendil (2003)
(telodipine) extended-rclease tablets prescribing information
The prevalence of hypertension is increasing steadily in the US, particularly among African Americans. It is now clear that a large proportion of patients are inadequately controlled, with many patients requiring at least two agents to achieve their target BP. Calcium channel blockers (CCBs), comprising two subclasses — dihydropyridines and non-dihydropyridines — have been for many years one of the mainstays of hypertension therapy. However, the use of CCBs as monotherapy has recently been overshadowed by the introduction of newer classes of agents such as angiotensin receptor blockers. Examining the pharmacologic and clinical effects of CCBs in essential hypertension and among specific patient groups (e.g. African Americans, patients with renal disease) paves the way for understanding why these agents are currently enjoying a resurgence in popularity as the basis for several fixed-dose combination regimens that promise to improve BP control and reduce the risk of cardiovascular events.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Dec 9, 2014
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.